196 results
8-K
EX-10.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
26 Jan 12
Entry into a Material Definitive Agreement
12:00am
, in an aggregate amount up to Seven Million Five Hundred Thousand Dollars ($7,500,000) (the “Term B Loan”) according to each Lender’s Term Loan Commitment … ”) according to each Lender’s Term Loan Commitment as set forth onSchedule 1.1 hereto. After repayment, the Term Loan may not be re-borrowed.”
2.2
8-K
EX-10.1
gl76m6
17 Oct 23
Entry into a Material Definitive Agreement
7:24pm
S-4
EX-2.1
ftn2hxg 479x
9 Jul 98
Registration of securities issued in business combination transactions
12:00am
8-K
EX-10.3
jaub ueijys1
26 Jan 11
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
4xlhhha
2 Feb 15
Departure of Directors or Certain Officers
12:00am
8-K
EX-99.1
45h5 z2iee
18 Nov 05
Ligand Pharmaceuticals to Explore Strategic Alternatives
12:00am
8-K
EX-99.2
soyfqyl
27 Mar 09
Important Notice Concerning Limitations on Your
12:00am
8-K
0vneg04
17 Oct 23
Entry into a Material Definitive Agreement
7:24pm
8-K
EX-99.1
7tjys69kvscmcghfd45
19 Nov 12
Other Events
12:00am
8-K
EX-99.1
9nsa4oeafb
21 Dec 09
Regulation FD Disclosure
12:00am
8-K
EX-99.1
b8j 763bqrschfdn
24 Sep 08
1 Joseph A. Mollica, Ph.D., Chairman of the Board, Interim President & CEO, Pharmacopeia John L. Higgins, President & CEO
12:00am
8-K
EX-99.1
tquon4gt9v
14 Dec 12
Other Events
12:00am